隨著新型冠狀病毒肺炎（COVID-19）在國內(nèi)快速爆發(fā)，國家衛(wèi)生健康委員會(huì)辦公廳和國家中醫(yī)藥管理局辦公室推出不同的診療方案。目前根據(jù)COVID-19危重癥患者的臨床特征及中醫(yī)辨證認(rèn)為氣陰兩虛證為主要證型之一，生脈散為備選中成藥。注射用益氣復(fù)脈（凍干）是生脈散的現(xiàn)代制劑，對COVID-19的可能病理過程及注射用益氣復(fù)脈用于心血管疾病的COVID-19治療的藥效作用及臨床應(yīng)用可行性進(jìn)行了探討，以期為COVID-19的中醫(yī)治療提供參考。

As the rapid outbreak of epidemic novel coronavirus pneumonia (COVID-19) in China, National Health Commission of People's Republic of china and National Administration of Traditional Chinese Medicine have launched different programs of diagnosis and treatment. Currently, combining the clinical characteristics of critically patients, the syndrome differentiation of traditional Chinese medicine maintain that Qi-Yin deficiency is one of the main syndrome types, and Shengmai Powder is the main alternative Chinese traditional medicine. Yiqi Fumai lyophilized Injection (YQFM) is a modern preparation derived from Shengmai Powder. In the present study, we explored the potential pathological process of COVID-19. Meanwhile, the pharmacological effects as well as the possibility of clinical application of YQFM for the treatment of COVID-19 patients with cardiovascular diseases were also evaluated. This review will provide evidences for clinicians and patients in the treatment of COVID-19 using Chinese traditional treatment.

R259;R285.6

天津市科技計(jì)劃項(xiàng)目“注射用益氣復(fù)脈（凍干）標(biāo)準(zhǔn)提升成果轉(zhuǎn)化”（18YFCZZC00430）